Biomarkers /
SUZ12
Overview
SUZ12 polycomb repressive complex 2 subunit (SUZ12) is a gene that encodes a protein that functions in the methylation of histone H3 and subsequent transcriptional repression of the target gene. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as breast cancer, endometrial cancer, and skin cancer.
SUZ12 is altered in 1.09% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].
The most common alterations in SUZ12 are SUZ12 Amplification (0.12%), SUZ12 Loss (0.07%), SUZ12 G39S (0.13%), SUZ12 A66T (0.18%), and SUZ12 A33V (0.06%) [3].
Clinical Trials
Significance of SUZ12 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.